News
Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing

- Series C financing brings total capital raised in the last 12 months to over US$ 400 million (>RMB 2.5 billion)
- The proceeds will support the continued development and expansion of Clover's pipeline of protein-based vaccines and biologic cancer therapies
CHENGDU, China, Feb. 22, 2021 /PRNewswire/ — Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing transformative biologics as vaccines and therapeutics for the world's most debilitating diseases, today announced the completion of an oversubscribed $230 million Series C financing. This financing round brings Clover's total capital raised in the last 12 months to over $400 million (over RMB 2.5 billion). The Series C round was co-led by GL Ventures and Temasek, with participation from Oceanpine Capital, OrbiMed and existing investor Delos Capital.
The proceeds will support the continued development and expansion of Clover's pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag© technology platform. Clover expects to initiate a global Phase 2/3 efficacy trial for SCB-2019 (S-Trimer), its COVID-19 vaccine candidate, in the first half of 2021 and has initiated production planning for potentially hundreds of millions of vaccine doses in 2021. Clover has also initiated development of additional vaccine programs including multivalent SARS-CoV-2 (covering multiple variants), rabies and influenza. SCB-313, a novel TRAIL-Trimer fusion protein targeting intracavitary malignancies (including malignant ascites), is in multiple ongoing Phase I clinical trials in Australia and China, with encouraging efficacy signals and a favorable safety profile demonstrated to-date. Clover also expects to advance multiple new pipeline products to the clinic in 2021 and further expand its in-house R&D and cGMP commercial biomanufacturing capabilities.
Joshua Liang, Chief Executive Officer and Board Director of Clover said, “Our goal has always been to bring our innovative vaccines and biologic therapies to the world by leveraging our proprietary Trimer-Tag© platform technology, state-of-the art cGMP biomanufacturing capabilities, and passionate team of over 500 scientists, experienced industry professionals and advisors. We look forward to using the proceeds from this financing round to accelerate development of our pipeline, expand our in-house R&D and biomanufacturing capabilities and move closer to our mission of improving the quality of life and wellbeing for patients around the world.”
Michael Yi, Co-CIO and Partner of Hillhouse Capital, said: “We are pleased to support the continuous development of Clover's promising pipeline, centered on its novel Trimer-Tag© technology platform. Clover has had a tremendous year of growth with the rapid advancement of the COVID-19 S-Trimer vaccine candidate through clinical development, and we look forward to potentially seeing the Company provide this much-needed vaccine to communities in need across the globe. In addition, Clover's robust and differentiated pipeline of vaccines and biologic therapeutics hold great promise to make a difference in other infectious diseases and oncology indications.”
About Clover Biopharmaceuticals
Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases, as well as viral vaccines. Having raised more than USD $400 million in total capital since 2020, Clover is utilizing its proprietary Trimer-Tag© technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house GMP biomanufacturing capabilities which has been certificated by a Qualified Person (QP) within the European Union (EU) to support GMP production of its biologic products. For more information, please visit our website: www.cloverbiopharma.com.
About Trimer-Tag© Technology
Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. Many major disease targets are trimerization-dependent such as the tumor necrosis factor (TNF) superfamily (involved in extrinsic apoptosis, immune co-stimulation and inflammation) as well as enveloped RNA virus antigens responsible for entry into host cells. Clover is using its Trimer-Tag© technology with global IP position to develop recombinant trimerized fusion proteins that can effectively target these previously undruggable pathways.
About GL Ventures
GL Ventures focuses on early-stage innovative companies in healthcare, software services, consumer Internet, emerging consumer brands and services. The GL Ventures team is passionate about partnering with visionary entrepreneurs to create industry leaders that stand the test of time. GL Ventures is the early stage affiliate of Hillhouse Capital, and we have been investing with innovators across the world since 2005. We were one of the earliest investors into some of the largest global companies today, including BeiGene, Zoom, Meituan, JD, Woowa Brothers and many more.
About Temasek
Temasek is an investment company with a net portfolio value of S$306 billion (RMB1.52t) as at 31 March 2020. Our three roles as an Investor, Institution and Steward, as defined in our Temasek Charter, shape our ethos to do well, do right and do good. Our investment philosophy is anchored around four key themes: Transforming Economies; Growing Middle Income Populations; Deepening Comparative Advantages; and Emerging Champions. We actively seek sustainable solutions to address present and future challenges, as we capture investment and other opportunities that help to bring about a better, smarter and more sustainable world. Headquartered in Singapore, we have 11 offices around the world. For more information on Temasek, please visit www.temasek.com.sg.
Clover Biopharmaceuticals Contacts:
Cindy Min
Vice President, Public Affairs
[email protected]
Katelyn Caruso-Sharpe
LifeSci Communications
[email protected]
518-496-6302
View original content to download multimedia:http://www.prnewswire.com/news-releases/clover-biopharmaceuticals-raises-230-million-in-oversubscribed-series-c-financing-301232943.html
SOURCE Clover Biopharmaceuticals
News
CGI's Asia Pacific Delivery Centers of Excellence appraised at CMMI Level 5 in Version 2.0 for Services

BANGALORE, India, Feb. 23, 2021 /PRNewswire/ — CGI (NYSE: GIB) (TSX: GIB.A) announced that its India and Philippines delivery centers have been appraised at Level 5 in Version 2.0 of the CMMI Institute's Capability Maturity Model Integration (CMMI ®) for Services. The appraisal was performed by KPMG.

CMMI is a Capability Maturity Improvement framework that provides organizations with the essential elements of effective processes that ultimately improve performance. CGI's appraisal at Maturity Level 5 indicates that CGI is performing at an “optimizing” level, continually improving its processes by using a quantitative approach to understand the variation in the process and the causes of process outcomes.
“Achieving CMMI® level 5 for Services signifies another major milestone in our commitment to provide the highest quality of service and operational excellence as we work together with clients to help them modernize their IT supply chains,” said George Mattackal, President of CGI's Asia Pacific Global Delivery Centers of Excellence. “Our emphasis on continuous improvement translates to greater operational efficiency and added value for clients as they seek to digitize their operations to become more resilient and provide greater value to their customers.”
In addition to process maturity, CGI's delivery centers in the Asia Pacific provide a robust mix of managed IT and IP-based services. They have co-created with clients innovative methods and tools, such as the Application Services Optimisation Programme (ASOP), an end-to-end framework for the delivery of application services, Sofia, a self-building chatbot platform, and SiteReliability 360, a proactive monitoring and problem resolution platform for hybrid cloud environments.
In Asia Pacific, CGI employs more than 15,000 consultants across major cities in India, Malaysia, and the Philippines to provide global delivery support that accelerate client goals and sustain business outcomes. The appraisal demonstrates the high level of process maturity underlying CGI's service delivery and culture of continuous improvement based on the CGI Management Foundation.
About CGI
Founded in 1976, CGI is among the largest independent IT and business consulting services firms in the world. With 76,000 consultants and other professionals across the globe, CGI delivers an end-to-end portfolio of capabilities, from strategic IT and business consulting to systems integration, managed IT and business process services, and intellectual property solutions. CGI works with clients through a local relationship model complemented by a global delivery network that helps clients digitally transform their organizations and accelerate results. CGI Fiscal 2020 reported revenue is C$12.16 billion and CGI shares are listed on the TSX (GIB.A) and the NYSE (GIB). Learn more at cgi.com.
About CMMI Institute
CMMI Institute is the global leader in the advancement of best practices in people, process and technology. CMMI Institute's promise is to inspire cultures of continuous improvement that elevate performance and create sustainable competitive advantage. CMMI Institute offers market-driven solutions that provide insights for baselining and optimizing key organizational capabilities, cyber maturity, and data assets to evaluate business performance.
Logo – https://mma.prnewswire.com/media/1063988/CGI_Logo.jpg
News
Augusta Gold Grants Stock Options

VANCOUVER, BC, Feb. 22, 2021 /PRNewswire/ – Augusta Gold Corp. (OTCQB: AUGG) (CSE: G) (FSE: 11B) (“Augusta” or the “Company”) is pleased to announce the grant of 5.8 million stock options to officers, directors and employees of the Company, pursuant to the terms of the Company's Stock Option Plan. The Options have an exercise price of C$3.00 per share and expire five (5) years from the date of grant.
The Company has also changed its trading symbol on the OTCQB from BFGCD to AUGG. With the recent name change of the Company it was appropriate that the ticker symbol represented this shift.
About Augusta Gold
Augusta Gold is a rapidly growing exploration and development company focused on building a long-term business that delivers stakeholder value through developing the Bullfrog Gold Project and pursing accretive M&A opportunities. The Bullfrog Gold Project is located in the prolific Bullfrog district approximately 120 miles north-west of Las Vegas, Nevada and 4 miles west of Beatty, Nevada. The Company controls approximately 7,800 acres of mineral rights including the Bullfrog and Montgomery-Shoshone deposits and has further identified significant additional mineralization around the existing pits and defined several exploration targets that could further enhance the Project. The Company is led by a management team and board of directors with a proven track record of success in financing and developing mining assets and delivering shareholder value. For more information please visit www.augustagold.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/augusta-gold-grants-stock-options-301232971.html
SOURCE Augusta Gold Corp.
News
CoinGate: Buy most popular Indian E-Gift Cards with Bitcoin & other cryptocurrency

VILNIUS, Lithuania, Feb. 23, 2021 /PRNewswire/ — Indian cryptocurrency holders can now buy a wide range (+140) of locally redeemable e-gift cards with Bitcoin or other ten cryptocurrency options on CoinGate.
These e-vouchers include some notable brands in India like Flipkart, BigBazaar, SPAR, Arvind, Lifestyle, ALDO, Central, Shoppers Stop, Homecentre, Bata, Pantaloons and more.
All these vouchers and more are in stock and up for grabs on CoinGate's Gift Card store right now.
All purchased gift cards are sent to the user's provided email address immediately after payment. Get it for yourself, or send it as a gift to someone else directly and instantly.
Your first time paying with crypto? Use these step-by-step instructions to guide you.
India's endlessly growing gift card industry
In India, the gift card market has spread like wildfire over the last couple of years, growing steadily and recording a compound annual growth rate (CAGR) of 25.5% between 2015 and 2019.
The use of electronic gift cards accelerated even more during COVID-19 outbreak as they proved to be a convenient way to give presents on special occasions while social distancing, or even transfer value across regions without using costly traditional payment channels like banks or money transfer services.
Looking forward to 2024, India's market for electronic vouchers is estimated to reach 9.34 billion USD in value by then, compared to 3,44 billion USD in 2019 due to their steadily rising popularity and increasing overall adoption in daily lives.
Indian e-gift cards for Bitcoin, Litecoin, Ether & more
And now, CoinGate is adding fuel to this wildfire by enabling the inventory of more than 140 different e-gift cards for crypto-friendly shoppers from India to obtain using their cryptocurrency portfolios.
Our team is excited to provide India with an opportunity to put their crypto-assets to fair use, knowing that the country is still in limbo about the status of cryptocurrencies which makes them harder to use.
Now, after almost a year since its Supreme Court struck down RBI banking ban on crypto, Indian traders and exchange operators have new hope for sensible action from the government.
Even though Indian crypto users are struggling to find common ground with traditional payment instruments, we are happy to relieve some pain by providing an easy way to realize cryptocurrency value through gift cards.
Happy spending and hopefully you'll enjoy our service!
Photo – https://mma.prnewswire.com/media/1442308/buy_cryptocurrency_gift_cards_india_coingate.jpg